drugset / Trial / NCT06697184

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184

Phase 1/2 Recruiting 258 enrolled BeOne Medicines
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Timeline

Start
2025-01-23
Primary completion
2029-11-30
Completion
2032-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sonrotoclax Other / unclassified Oral
Background Zanubrutinib Small molecule Oral